170 related articles for article (PubMed ID: 36763783)
1. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
[TBL] [Abstract][Full Text] [Related]
3. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
Mason KJ; Williams S; Yiu ZZN; McElhone K; Ashcroft DM; Kleyn CE; Jabbar-Lopez ZK; Owen CM; Reynolds NJ; Smith CH; Wilson N; Warren RB; Griffiths CEM
Br J Dermatol; 2019 Aug; 181(2):256-264. PubMed ID: 30628069
[TBL] [Abstract][Full Text] [Related]
4. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
[TBL] [Abstract][Full Text] [Related]
5. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN; Ashcroft DM; Evans I; McElhone K; Lunt M; Smith CH; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
Br J Dermatol; 2019 Feb; 180(2):329-337. PubMed ID: 30070708
[TBL] [Abstract][Full Text] [Related]
6. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
[TBL] [Abstract][Full Text] [Related]
7. The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
Br J Dermatol; 2023 Apr; 188(5):e35. PubMed ID: 37078764
[No Abstract] [Full Text] [Related]
8. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
9. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
[TBL] [Abstract][Full Text] [Related]
10. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
[TBL] [Abstract][Full Text] [Related]
11. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Takeshita J; Wang S; Shin DB; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Stierstorfer MB; Brod BA; Schleicher SM; Robertson AD; Linn KA; Shinohara RT; Troxel AB; Van Voorhees AS; Gelfand JM
J Am Acad Dermatol; 2014 Dec; 71(6):1167-75. PubMed ID: 25260564
[TBL] [Abstract][Full Text] [Related]
13. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
14. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
[TBL] [Abstract][Full Text] [Related]
15. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
Reich K; Augustin M; Thaçi D; Pinter A; Leutz A; Henneges C; Schneider E; Schacht A; Dossenbach M; Mrowietz U
Br J Dermatol; 2020 Apr; 182(4):869-879. PubMed ID: 31376153
[TBL] [Abstract][Full Text] [Related]
16. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
[No Abstract] [Full Text] [Related]
17. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
[TBL] [Abstract][Full Text] [Related]
18. Oral fumaric acid esters for psoriasis.
Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review.
van Winden MEC; van der Schoot LS; van de L'Isle Arias M; van Vugt LJ; van den Reek JMPA; van de Kerkhof PCM; de Jong EMGJ; Lubeek SFK
JAMA Dermatol; 2020 Nov; 156(11):1229-1239. PubMed ID: 32822455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
